Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769558 · ClinicalTrials.gov registry record
A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 264
- Enrollment target
NCT03769558: Completed study, sponsored by Bristol-Myers Squibb.
NCT03769558 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 264 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03769558 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 264 participants
- Enrollment target
Study Summary
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2016-07-12 |
| Est. Completion | 2016-09-30 |
What the finished NCT03769558 record still lists
NCT03769558 is an observational study that tracks outcomes without assigning an intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03769558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03769558 about?
NCT03769558 is a clinical study titled "A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur". This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
What is the current status of trial NCT03769558?
This trial is currently completed. The enrollment target is 264 participants. The study started on 2016-07-12. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT03769558?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03769558?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI